Essais liés11clinical trials
VilleAtlantalocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06907875

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
Pitolisant Oral Tablet Myopathies Phase 2 NCT04886518 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 COMPLETED
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD Myopathies À vérifier NCT05683379 AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD ACTIVE_NOT_RECRUITING
SGT-003 Myopathies Phase 1/2 NCT06138639 A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) RECRUITING
AOC 1020 Myopathies Phase 2 NCT06547216 FORTITUDE-OLE — Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) ACTIVE_NOT_RECRUITING
AOC 1020 Myopathies Phase 1/2 NCT05747924 FORTITUDE — Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) COMPLETED
EPI-321 Myopathies Phase 1/2 NCT06907875 FSHD — A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy ACTIVE_NOT_RECRUITING
RGX-202 Myopathies Phase 2/3 NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) ACTIVE_NOT_RECRUITING
CDLink — CureDuchenne Link®: A Resource for Research Myopathies À vérifier NCT04972604 CDLink — CureDuchenne Link®: A Resource for Research COMPLETED
Sevasemten 10 mg Myopathies Phase 2 NCT05291091 Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) ACTIVE_NOT_RECRUITING
Sevasemten Myopathies Phase 2 NCT06066580 MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy ENROLLING_BY_INVITATION
delpacibart zotadirsen Myopathies À vérifier NCT07250737 Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping AVAILABLE